Jiangsu Nanfang Medical

Nanwei Shares released its 2026 interim report, showing total operating revenue of 271 million yuan, down 11.51 percent year on year, and a net loss attributable to the parent company of 17.79 million yuan, with the loss widening by 4.82 million yuan compared with the same period last year. Net cash inflow from operating activities was 30.12 million yuan, down 14.42 percent year on year. The company's asset-liability ratio rose to 81.31 percent, gross margin was 10.35 percent, return on equity was negative 11.16 percent, and diluted earnings per share was negative 0.06 yuan. The number of shareholders was 11,700, and the top ten shareholders held 56.95 percent of the total share capital.

Nanwei Shares released its 2026 half-year report on August 30. First-half operating revenue was 271 million yuan, down 11.5% year on year. Net profit attributable to the parent swung from a loss of 12.97 million yuan in the same period last year to a loss of 17.79 million yuan, while net profit attributable to the parent excluding non-recurring items widened from a loss of 15.4 million yuan to a loss of 18.61 million yuan. Second-quarter revenue was 116 million yuan, down 14.4% year on year, and the net loss attributable to the parent was 12.7 million yuan, wider than the 5.05 million yuan loss a year earlier. As of the end of the second quarter, total assets stood at 875 million yuan, down 5.7% from the end of the previous year, and net assets attributable to the parent were 159 million yuan, down 10.04%. The company said the revenue decline was mainly due to market factors that reduced revenue across product lines, the profit decline was caused by intense market competition and lower revenue, and the decrease in operating cash flow was due to a reduction in other cash received from operating activities. During the reporting period, research and development spending was 10.96 million yuan, aimed at consolidating its technical advantages in transdermal products.

Nanwei Shares announced that Li Yongzhong, a concert party of the controlling shareholder, pledged 8.08 million shares he holds, accounting for 99.9996% of his total holdings and 2.7954% of the company's total share capital. As of the announcement date, Li Yongzhong has pledged a cumulative total of 8.08 million shares. In the first quarter of 2026, Nanwei Shares achieved revenue of 155 million yuan and a net loss attributable to the parent company of 5.09 million yuan.

Nanwei Medical disclosed its earnings forecast, expecting a net loss attributable to shareholders of 16 million yuan in the first half of 2026, compared with a loss of 12.9677 million yuan in the same period last year. The net loss after deducting non-recurring items is expected to be 16.7 million yuan, compared with a loss of 15.4003 million yuan a year earlier. The company stated that due to factors such as international trade policies, geopolitical situations, and rising comprehensive costs of cross-border logistics, some export orders have decreased year-on-year, and operating revenue is expected to decline slightly compared with the same period last year. Meanwhile, the nitrile glove business of its wholly-owned subsidiary Anhui Nanwei Medical Supplies Company Limited has been unable to fully release production capacity due to the industry market environment, and the high fixed amortization costs from earlier production line investments have led to a net loss.